US › Healthcare

Quince Therapeutics, Inc. (QNCX)

US · Healthcare · Biotechnology

$27.01-0.59%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-75.5M

EPS

$-12.31

EPS estimate

$-33.26

EPS came in at -12.31 against a street estimate of -33.26 — a beat of 63.0%.

Key statistics

Market cap

$30.1M

Forward P/E

0.0

P/B

2.21

Book value

$-34.73

EPS (TTM)

$-210.84

52-week high

$910.00

52-week low

$15.10

50-day MA

$26.07

200-day MA

$168.06

Beta

1.31

Analyst view

Analysts rate Quince Therapeutics, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $77.20.

Shareholding

Insiders

2.90%

Institutions

34.90%

Largest institutional holders

Fund	Stake
Woodline Partners LP	2.56%
Shay Capital LLC	0.87%
Acadian Asset Management LLC	0.86%
Millennium Management LLC	0.35%
IEQ CAPITAL, LLC	0.29%
BlackRock Inc	0.23%
Vanguard Capital Management, LLC	0.23%
Squadron Capital Management LLC	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quince Therapeutics, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.